AN2 Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric E. Easom
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1800 El Camino Real Menlo Park CA United States of America 94027
- IPO Date
- Mar 25, 2022
- CIK
- 0001880438
- Website
- an2therapeutics.com
- Similar Companies
- Business
- AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative biologics for the treatment of cancer and autoimmune diseases. The company’s core products and services include proprietary biologic drug candidates derived from advance protein engineering and immunotherapy technologies. These product categories encompass antibody-based therapeutics designed to enhance immune system targeting and modulation, with a focus on next-generation oncology and inflammatory disorder treatments. AN2 Therapeutics operates primarily in the United States but aims at global markets through strategic collaborations and licensing partnerships. Founded in 2019 and headquartered in South San Francisco, California, AN2 Therapeutics develops a pipeline of engineered antibodies and protein therapeutics that harness novel mechanisms for improved safety and efficacy profiles compared to standard treatments. The company’s offerings include developmental biologics in preclinical and clinical stages targeting oncology indications such as solid tumors and hematologic malignancies, as well as autoimmune conditions. In recent major developments, AN2 Therapeutics has secured strategic partnerships to accelerate clinical trials and expand its research capabilities. The company has also progressed in its funding rounds, raising capital to support clinical development and manufacturing scale-up. Additionally, AN2 Therapeutics announced expansions in its pipeline with new product candidates entering preclinical stages, enhancing its therapeutic portfolio. These strategic expansions and fresh asset introductions mark a significant operational shift aiming to broaden therapeutic impact and market reach. The company increasingly positions itself as a specialized player in biologics innovation, leveraging advanced protein engineering to offer differentiated treatment options. AN2 Therapeutics maintains a focused presence in the biotechnology and pharmaceutical segments, targeting healthcare providers, research institutions, and strategic partners as key customers. Its corporate activities emphasize biologic drug development, licensing, technology partnerships, and investment in scalable manufacturing processes to support future commercialization. There are no publicly listed subsidiaries or parent company affiliations reported as of the most recent update.
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Stock Cools Off After 90% Rally
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights